MOXD1

Across TCGA pan-cancer cohorts, MOXD1 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated MOXD1 data layer compared with 20 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher MOXD1 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated MOXD1 expression acts as an unfavorable survival marker, although some lineages such as PDAC and LUAD show a favorable association.

PDAC, COAD, and CCRCC are the cancer types where MOXD1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Quartile	All	1.000	0.701	.002	26	view →
COAD	DFS	Median	III,IV	0.773	1.000	.031	18	view →
CCRCC	OS	Median	IV	0.167	0.784	.038	18	view →
LUAD	DFS	Tertile	All	0.832	0.512	.002	12	view →
GBM	OS	Median	All	0.291	0.447	.012	6	view →
LSCC	OS	Median	All	0.939	0.788	.008	4	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

MOXD1–PDAC (OS)

Open the PDAC breakdown →